| abstract |
PROBLEM TO BE SOLVED: To use 2,4,6-trifluoro-N- [6- (1-methyl-piperidine-4-ylcarbonyl) -pyridin-2-yl] -benzamide or a pharmacy thereof for use in the treatment of migraine. Provided are a pharmaceutical composition comprising a pharmaceutically acceptable salt and a pharmaceutically acceptable excipient or carrier. SOLUTION: A certain amount of 2,4,6-trifluoro-N- [6- (1-methyl-piperidin-4-ylcarbonyl) -pyridine-2-yl] -benzamide or pharmaceutically acceptable thereof. A pharmaceutical composition comprising a salt and a pharmaceutically acceptable excipient or carrier comprising 50-400 mg of the compound or a pharmaceutically acceptable salt thereof per dose for oral or rectal administration. For buccal, sublingual, nasal / intranasal, transdermal, subcutaneous, injection, intravenous or intramuscular administration, each dose contains up to 200 mg of the compound or a pharmaceutically acceptable salt thereof, plus one day. A pharmaceutical composition administered one, two or three times. [Selection diagram] None |